SG11201604860RA - Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof - Google Patents

Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof

Info

Publication number
SG11201604860RA
SG11201604860RA SG11201604860RA SG11201604860RA SG11201604860RA SG 11201604860R A SG11201604860R A SG 11201604860RA SG 11201604860R A SG11201604860R A SG 11201604860RA SG 11201604860R A SG11201604860R A SG 11201604860RA SG 11201604860R A SG11201604860R A SG 11201604860RA
Authority
SG
Singapore
Prior art keywords
hemophilia
factor
methods
fusion proteins
prophylactic treatment
Prior art date
Application number
SG11201604860RA
Inventor
Iris Jacobs
Debra Bensen-Kennedy
Christine Voigt
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Ltd filed Critical Csl Ltd
Publication of SG11201604860RA publication Critical patent/SG11201604860RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11201604860RA 2013-12-23 2014-12-01 Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof SG11201604860RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361919884P 2013-12-23 2013-12-23
PCT/AU2014/050388 WO2015095925A1 (en) 2013-12-23 2014-12-01 Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof

Publications (1)

Publication Number Publication Date
SG11201604860RA true SG11201604860RA (en) 2016-07-28

Family

ID=53477217

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201604860RA SG11201604860RA (en) 2013-12-23 2014-12-01 Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof

Country Status (12)

Country Link
US (1) US20160346366A1 (en)
EP (1) EP3086804A4 (en)
JP (1) JP2017502036A (en)
KR (1) KR20160093735A (en)
CN (1) CN105848669A (en)
AU (1) AU2014373618A1 (en)
BR (1) BR112016013577A2 (en)
CA (1) CA2934081A1 (en)
IL (1) IL245997A0 (en)
RU (1) RU2016129911A (en)
SG (1) SG11201604860RA (en)
WO (1) WO2015095925A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103140237A (en) 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 Factor ix polypeptides and methods of use thereof
EP3733199A1 (en) 2016-07-08 2020-11-04 CSL Behring Lengnau AG Subcutaneous administration of long-acting factor ix in humans
CN107759694B (en) * 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 Bispecific antibody, preparation method and application thereof
ES2963665T3 (en) * 2017-06-29 2024-04-01 CSL Behring Lengnau AG 21-Day Dosing Regimen for Fusion Proteins Comprising Factor IX and Human Albumin for the Prophylactic Treatment of Hemophilia and Methods Therefor
CN116036244B (en) * 2023-02-24 2023-09-19 北京基科晟斯医药科技有限公司 Use of recombinant human coagulation factor VIII-Fc fusion proteins for the treatment of hemophilia a comprising inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
WO2011003153A1 (en) * 2009-07-10 2011-01-13 Csl Limited Method of increasing the expression yield of vitamin k-dependent proteins
CN103140237A (en) * 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 Factor ix polypeptides and methods of use thereof

Also Published As

Publication number Publication date
EP3086804A1 (en) 2016-11-02
CA2934081A1 (en) 2015-07-02
JP2017502036A (en) 2017-01-19
WO2015095925A1 (en) 2015-07-02
AU2014373618A1 (en) 2016-07-21
IL245997A0 (en) 2016-07-31
RU2016129911A3 (en) 2018-08-28
US20160346366A1 (en) 2016-12-01
KR20160093735A (en) 2016-08-08
EP3086804A4 (en) 2017-07-19
CN105848669A (en) 2016-08-10
BR112016013577A2 (en) 2017-10-03
RU2016129911A (en) 2018-01-30

Similar Documents

Publication Publication Date Title
HK1248162A1 (en) Factor ix fusion proteins and methods of making and using same
IL280155A (en) Anti-siglec-8 antibodies and methods of use thereof
HK1217343A1 (en) Fusion immunomodulatory proteins and methods for making same
HK1220473A1 (en) Anti-alpha-synuclein antibodies and methods of use --
IL240034A0 (en) Pd-l1 and pd-l2-based fusion proteins and uses thereof
HK1220466A1 (en) Apelin fusion proteins and uses thereof
GB2535360B (en) Methods of preparing polyhemiaminals and polyhexahydrotriazines
EP2968551A4 (en) Fusion proteins and methods thereof
EP2945647A4 (en) Immunogenic wt-1 peptides and methods of use thereof
EP2877854A4 (en) Fusion proteins and methods thereof
EP2999474A4 (en) Therapeutic and method of use
PT2986633T (en) Methods for the expression of peptides and proteins
GB201315507D0 (en) Container and method of manufacture
IL245997A0 (en) Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof
SG11201509376PA (en) Glass structures and methods of creating and processing glass structures
HK1207960A1 (en) Human antibodies that bind human tnf-alpha and methods of preparing the same tnf-
IL243535A0 (en) Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof
EP2960248A4 (en) Method of isolating and purifying fusion protein comprising factor vii
EP2986725A4 (en) Methods and materials for encapsulating proteins
ZA201602304B (en) Modified anti-inflammatory proteins and method of use
GB201321911D0 (en) N-Glycosylation of peptides and proteins
GB201318313D0 (en) N-Glycosylation of peptides and proteins
AU2013903588A0 (en) Modified anti-inflammatory proteins and method of use